Catálogo de publicaciones - revistas
Alzheimer's and Dementia: The Journal of the Alzheimer's Association
Resumen/Descripción – provisto por la editorial en inglés
The mission of Alzheimer's & Dementia: Journal of the Alzheimer's Association is to bridge the knowledge gaps across a wide range of bench-to-bedside investigation. The journal publishes the results of studies in: behavior, biochemistry, genetics, molecular biology, pharmacology, physiology, protein chemistry, neurology, neuropathology, psychiatry, geriatrics, neuropsychology, epidemiology, sociology, health services research, health economics, political science and public policy. Content emphasizes interdisciplinary investigations, integrative/translational articles, related to: etiology, risk factors, early detection, disease modifying interventions, prevention of dementia and applications of new technologies in health services. The journal publishes • comprehensive reviews; • research articles; • information on clinical trials; • short reports;• in-depth perspectives/open-peer commentaries; • theoretical and/or translational papers that attempt integrate knowledge across discipline;
• history & politics of science/brief biographies and, • abstracts of papers presented at international meetings. Negative results, particularly clinical trials, are published as short communications.
The ultimate objective is to create a novel forum for: • rapid communication of new findings, ideas or perspectives; • disseminating knowledge, across the spectrum of basic to clinical studies, necessary for optimal translation of research findings into practical applications/interventions; • integrating knowledge across disciplines; • increase knowledge in diverse disciplines to promote early detection/diagnosis and/or interventions; • formulating new theories and/or strategies for the rigorous testing of theories or their predictions; • identifying promising new directions of research and, • providing the scientific impetus for new initiatives; or public policies concerning research on prevention and new models of health services.
Alzheimer's & Dementia is indexed/abstracted in Index Medicus/MEDLINE, Scopus, Science Citation Index Expanded (SciSearch®), Current Contents®/Clinical Medicine, Neuroscience Citation Index®, and Journal Citation Reports/Science Edition.
Palabras clave – provistas por la editorial
No disponibles.
Disponibilidad
| Institución detectada | Período | Navegá | Descargá | Solicitá |
|---|---|---|---|---|
| No detectada | desde ene. 2005 / hasta dic. 2023 | Wiley Online Library |
Información
Tipo de recurso:
revistas
ISSN impreso
1552-5260
ISSN electrónico
1552-5279
Editor responsable
Elsevier
País de edición
Países Bajos
Fecha de publicación
2005-
Cobertura temática
Tabla de contenidos
Mild cognitive impairment and cognitive impairment, no dementia: Part B, therapy
Fadi Massoud; Sylvie Belleville; Howard Bergman; John Kirk; Howard Chertkow; Ziad Nasreddine; Yves Joanette; Morris Freedman
Palabras clave: Health Policy; Developmental Neuroscience; Epidemiology; Cellular and Molecular Neuroscience; Geriatrics and Gerontology; Psychiatry and Mental health; Clinical Neurology.
Pp. 283-291
Trajectories of Alzheimer disease-related cognitive measures in a longitudinal sample
Murat Bilgel; Yang An; Andrew Lang; Jerry Prince; Luigi Ferrucci; Bruno Jedynak; Susan M. Resnick
Palabras clave: Health Policy; Developmental Neuroscience; Epidemiology; Cellular and Molecular Neuroscience; Geriatrics and Gerontology; Psychiatry and Mental health; Clinical Neurology.
Pp. 735-742.e4
Subjective memory decline predicts greater rates of clinical progression in preclinical Alzheimer's disease
Rachel F. Buckley; Paul Maruff; David Ames; Pierrick Bourgeat; Ralph N. Martins; Colin L. Masters; Stephanie Rainey-Smith; Nicola Lautenschlager; Christopher C. Rowe; Greg Savage; Victor L. Villemagne; Kathryn A. Ellis;
Palabras clave: Health Policy; Developmental Neuroscience; Epidemiology; Cellular and Molecular Neuroscience; Geriatrics and Gerontology; Psychiatry and Mental health; Clinical Neurology.
Pp. 796-804
P2-233: BETTER MEASUREMENT FOR IMPROVED DIAGNOSIS AND MANAGEMENT OF ALZHEIMER'S DISEASE: UPDATE ON THE EMPIR NEUROMET PROJECT
Milena Quaglia; Vittorio Bellotti; Stefan Cano; Adam Cryar; Katherine Deane; Carla Divieto; Ariane Fillmer; Chiara Giangrande; Theresa Köbe; Sylvain Lehmann; Jeanette Melin; Susan Pang; Helen Parkes; Leslie Pendrill
Palabras clave: Health Policy; Developmental Neuroscience; Epidemiology; Cellular and Molecular Neuroscience; Geriatrics and Gerontology; Psychiatry and Mental health; Clinical Neurology.
Pp. P759-P760
doi: 10.1002/alz.058593
Accelerated epigenetic aging in adults with Down Syndrome in the Argentine population
Giulia Solange Clas; Elmer A. Fernández; Juan Carlos Guillermo Vázquez; Lucia Pertierra; Nahuel Magrath Guimet; Fernanda Tapajoz; Belén Helou; Tatiana Itzcovich; Micaela Barbieri Kennedy; Horacio Martinetto; Gustavo Sevlever; Ricardo Francisco Allegri; Ezequiel Surace
Palabras clave: Psychiatry and Mental health; Cellular and Molecular Neuroscience; Geriatrics and Gerontology; Neurology (clinical); Developmental Neuroscience; Health Policy; Epidemiology.
Pp. No disponible
doi: 10.1002/alz.12505
Different rates of cognitive decline in autosomal dominant and late‐onset Alzheimer disease
Virginia D. Buckles; Chengjie Xiong; Randall J. Bateman; Jason Hassenstab; Ricardo Allegri; Sarah B. Berman; Jasmeer P. Chhatwal; Adrian Danek; Anne M. Fagan; Bernardino Ghetti; Alison Goate; Neill Graff‐Radford; Mathias Jucker; Johannes Levin; Daniel S. Marcus; Colin L. Masters; Lena McCue; Eric McDade; Hiroshi Mori; Krista L. Moulder; James M. Noble; Katrina Paumier; Oliver Preische; John M. Ringman; Nick C. Fox; Stephen Salloway; Peter R. Schofield; Ralph Martins; Jonathan Vöglein; John C. Morris;
Palabras clave: Psychiatry and Mental health; Cellular and Molecular Neuroscience; Geriatrics and Gerontology; Neurology (clinical); Developmental Neuroscience; Health Policy; Epidemiology.
Pp. No disponible
doi: 10.1002/alz.12644
Changes in cognitive functioning after COVID‐19: A systematic review and meta‐analysis
Lucia Crivelli
; Katie Palmer; Ismael Calandri; Alla Guekht; Ettore Beghi; William Carroll; Jennifer Frontera; David García‐Azorín; Erica Westenberg; Andrea Sylvia Winkler; Francesca Mangialasche; Ricardo F. Allegri; Miia Kivipelto
Palabras clave: Psychiatry and Mental health; Cellular and Molecular Neuroscience; Geriatrics and Gerontology; Neurology (clinical); Developmental Neuroscience; Health Policy; Epidemiology.
Pp. No disponible
doi: 10.1002/alz.12638
2022 Alzheimer's disease facts and figures
<jats:title>Abstract</jats:title><jats:p>This article describes the public health impact of Alzheimer's disease (AD), including incidence and prevalence, mortality and morbidity, use and costs of care, and the overall impact on family caregivers, the dementia workforce and society. The Special Report discusses consumers' and primary care physicians' perspectives on awareness, diagnosis and treatment of mild cognitive impairment (MCI), including MCI due to Alzheimer's disease. An estimated 6.5 million Americans age 65 and older are living with Alzheimer's dementia today. This number could grow to 13.8 million by 2060 barring the development of medical breakthroughs to prevent, slow or cure AD. Official death certificates recorded 121,499 deaths from AD in 2019, the latest year for which data are available. Alzheimer's disease was officially listed as the sixth‐leading cause of death in the United States in 2019 and the seventh‐leading cause of death in 2020 and 2021, when COVID‐19 entered the ranks of the top ten causes of death. Alzheimer's remains the fifth‐leading cause of death among Americans age 65 and older. Between 2000 and 2019, deaths from stroke, heart disease and HIV decreased, whereas reported deaths from AD increased more than 145%. More than 11 million family members and other unpaid caregivers provided an estimated 16 billion hours of care to people with Alzheimer's or other dementias in 2021. These figures reflect a decline in the number of caregivers compared with a decade earlier, as well as an increase in the amount of care provided by each remaining caregiver. Unpaid dementia caregiving was valued at $271.6 billion in 2021. Its costs, however, extend to family caregivers’ increased risk for emotional distress and negative mental and physical health outcomes — costs that have been aggravated by COVID‐19. Members of the dementia care workforce have also been affected by COVID‐19. As essential care workers, some have opted to change jobs to protect their own health and the health of their families. However, this occurs at a time when more members of the dementia care workforce are needed. Average per‐person Medicare payments for services to beneficiaries age 65 and older with AD or other dementias are almost three times as great as payments for beneficiaries without these conditions, and Medicaid payments are more than 22 times as great. Total payments in 2022 for health care, long‐term care and hospice services for people age 65 and older with dementia are estimated to be $321 billion. A recent survey commissioned by the Alzheimer's Association revealed several barriers to consumers’ understanding of MCI. The survey showed low awareness of MCI among Americans, a reluctance among Americans to see their doctor after noticing MCI symptoms, and persistent challenges for primary care physicians in diagnosing MCI. Survey results indicate the need to improve MCI awareness and diagnosis, especially in underserved communities, and to encourage greater participation in MCI‐related clinical trials.</jats:p>
Palabras clave: Psychiatry and Mental health; Cellular and Molecular Neuroscience; Geriatrics and Gerontology; Neurology (clinical); Developmental Neuroscience; Health Policy; Epidemiology.
Pp. 700-789
doi: 10.1002/alz.12640
Screening and enrollment of underrepresented ethnocultural and educational populations in the Alzheimer's Disease Neuroimaging Initiative (ADNI)
Miriam T. Ashford; Rema Raman; Garrett Miller; Michael C. Donohue; Ozioma C. Okonkwo; Monica Rivera Mindt; Rachel L. Nosheny; Godfrey A. Coker; Ronald C. Petersen; Paul S. Aisen; Michael W. Weiner;
Palabras clave: Psychiatry and Mental health; Cellular and Molecular Neuroscience; Geriatrics and Gerontology; Neurology (clinical); Developmental Neuroscience; Health Policy; Epidemiology.
Pp. 2603-2613
doi: 10.1002/alz.12912
Cross‐sectional and longitudinal comparisons of biomarkers and cognition among asymptomatic middle‐aged individuals with a parental history of either autosomal dominant or late‐onset Alzheimer's disease
Chengjie Xiong; Lena M. McCue; Virginia Buckles; Elizabeth Grant; Folasade Agboola; Dean Coble; Randall J. Bateman; Anne M Fagan; Tammie L. S. Benzinger; Jason Hassenstab; Suzanne E. Schindler; Eric McDade; Krista Moulder; Brian A. Gordon; Carlos Cruchaga; Gregory S. Day; Takeshi Ikeuchi; Kazushi Suzuki; Ricardo F. Allegri; Jonathan Vöglein; Johannes Levin; John C. Morris;
Palabras clave: Psychiatry and Mental health; Cellular and Molecular Neuroscience; Geriatrics and Gerontology; Neurology (clinical); Developmental Neuroscience; Health Policy; Epidemiology.
Pp. No disponible